secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001104659-23-126639
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GSBR-1290 Phase 2a meets endpoints; significant HbA1c and weight reductions in T2DM and obesity
--------------------------------------------------------------------------------

- HbA1c reduction: -1.01% to -1.02% placebo-adjusted at Week 12 (p≤0.008).
- Weight loss: T2DM -3.26% to -3.51% placebo-adjusted at Week 12; obesity -4.74% at Week 8 (p<0.0001).
- No treatment-related SAEs; 2.8% discontinuation rate due to AEs; GI events most common.
- Full 12-week obesity data expected Q2 2024; Phase 2b obesity study to start H2 2024.
- Toxicology studies show >100-fold safety margin; Japanese bridging study supports global plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923126639/0001104659-23-126639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923126639/tm2329572d16_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-126639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer